Liposomal Calcium AKG is a formulation designed to enhance the bioavailability of alpha-ketoglutarate (AKG), a key metabolite in the Krebs cycle that declines with age. By replenishing AKG, it may support cellular energy production, inhibit mTOR, and promote metabolic health, processes linked to longevity in animal models. The liposomal encapsulation aims to protect the compound from gastric degradation and improve absorption.
Verdict
A promising but speculative intervention based on strong animal data.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Low
EVIDENCE GRADE
C
MONTHLY COST
$60 - $120
Protocol
- Typical daily doses range from 300 mg to 500 mg, taken with or without food, reflecting the enhanced bioavailability of the liposomal form.
Flags
- Liposomal delivery may significantly alter absorption rates compared to standard Ca-AKG.
- Individuals with kidney disease or hypercalcemia should consult a physician before use.
- Long-term human safety data for healthspan applications is not yet available.